Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry

Eirini Zacharopoulou, MD, PhD,* Eleni Orfanoudaki, MD, PhD,† Maria Tzouvala, MD, PhD,* George Tribonias, MD, PhD,* Georgios Kokkotis, MD, MSc,† Vassiliki Kitsou, MD,‡ Foteini Almpani, MD,§ Aggeliki Christidou, MD,§ Nikolaos Viazis, MD, PhD,§ Gerassimos J Mantzaris, MD, PhD,‖ Maria Tsafaridou, MD,¶ Konstantinos Karmiris, MD, PhD,¶ Angeliki Theodoropoulou, MD,¶ Evgenia Papathanasiou, MD,† Evanthia Zampeli, MD, PhD,‖ Spyridon Michopoulos, MD, PhD,§,‖ Georgios Michalopoulos, MD, PhD,‖ Efrossini Laoudi, MD,‖ Pantelis Karatzas, MD, PhD,‖ Ioannis E Koutroubakis, MD, PhD,‖ and Giorgos Bamias, MD, PhD‡,¶

From the *Department of Gastroenterology, General Hospital of Nikaia Piraeus “Agios Panteleimon,” General Hospital Dytikis Attikis “Agia Varvara,” Athens, Greece †Department of Gastroenterology, University Hospital of Heraklion, Medical School, University of Crete, Heraklion Crete, Greece ‡GI Unit, 3rd Academic Department of Internal Medicine, National and Kapodistrian University of Athens- “Sotiria” General Hospital, Athens, Greece §Department of Gastroenterology, General Hospital of Athens, Evangelismos, Ophthalmitreon Athinon, Polykliniki, Athens, Greece ¶Department of Gastroenterology, Venizelio General Hospital, Heraklion Crete, Greece‖Department of Gastroenterology, General Hospital of Athens “Alexandra,” Athens, Greece **Department of Gastroenterology, General Hospital of Piraeus “Tzaneio,” Piraeus, Greece ††Department of Gastroenterology, National and Kapodistrian University of Athens, General Hospital of Athens “Laiko,” Athens, Greece ‡‡Department of Gastroenterology, 401 General Army Hospital of Athens, Athens, Greece §§Department of Gastroenterology, University Hospital of Patras, Patra, Greece ¶¶StArtBio PC Molecular Diagnostics and Biotechnology Services, Athens, Greece

Address correspondence to: Giorgos Bamias, MD, PhD, Associate Professor of Gastroenterology, GI Unit, 3rd Academic Dpt. of Internal Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, 152 Mesogeion av. 11527, Tel +30 2107763100, Athens, Greece (gbamias@gmail.com).

Background: Four EMA-approved vaccines against SARS-CoV-2 are currently available. Data regarding antibody responses to initial vaccination regimens in patients with inflammatory bowel diseases (IBD) are limited.

Methods: We conducted a prospective, controlled, multicenter study in tertiary Greek IBD centers. Participating patients had completed the initial vaccination regimens (1 or 2 doses, depending on the type of COVID-19 vaccine) at least 2 weeks before study enrolment. Anti-S1 IgG antibody levels were measured. Demographic and adverse events data were collected.

Results: We tested 403 patients (Crohn’s disease, 58.9%; male, 53.4%; median age, 45 years) and 124 healthy controls (HCs). Following full vaccination, 98% of patients seroconverted, with mRNA vaccines inducing higher seroconversion rates than viral vector vaccines (P = .021). In total, IBD patients had lower anti-S1 levels than HCs (P < .001). In the multivariate analysis, viral vector vaccines (P < .001), longer time to antibody testing (P < .001), anti-TNFα treatment (P = .013), and age (P = .016) were independently associated with lower anti-S1 titers. Vedolizumab monotherapy was associated with higher antibody levels than anti-TNFα or anti-interleukin-12/IL-23 monotherapy (P = .023 and P = .032). All anti-SARS-CoV-2 vaccines were safe.

Conclusions: Patients with IBD have impaired antibody responses to anti-SARS-CoV-2 vaccination, particularly those receiving viral vector vaccines and those on anti-TNFα treatment. Older age also hampers antibody production after vaccination. For those low-response groups, administration of accelerated or prioritized booster vaccination may be considered.

Lay Summary
This is a multicenter study on IBD patients after COVID-19 vaccination and anti-S1 IgG antibody levels measurement. Patients with IBD have lower antibody responses than healthy controls, particularly those receiving viral vector vaccines and those on anti-TNFα or combination treatment.

Key Words: IBD, Crohn’s disease, ulcerative colitis, COVID-19 vaccines, antibody response
**Introduction**

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes Corona virus disease (COVID)-19 was first detected in December 2019 in the Wuhan region, China, and has evolved into pandemic status beginning March 2020.1 It prompted immediate efforts for the development of anti-SARS-CoV-2-vaccines. Although vaccine production typically requires years of research and testing before reaching the clinic, 114 anti-SARS-CoV-vaccines are currently being tested in clinical trials, of which 48 have reached the final stages of testing, and 28 have already been authorized or approved for use in different countries.

In the European Union (EU), 4 vaccines are currently approved by European Medicines Agency (EMA). Those include both mRNA (mRNA-1273 [Moderna/NIH], BNT162b2 [Pfizer-BioNTEch]) and viral vector vaccines (Ad26.Cov2.S [J&J], ChAdOx1 [AstraZeneca]).2–4 The characteristics of the 4 available vaccines are shown in Supplementary table 1. The initial national COVID-19 vaccination program in Greece included a 2-dose regimen for mRNA vaccines and ChAdOx1 or a 1-dose regimen for Ad26.Cov2.S. Immunocompromised patients have preferentially received vaccination with mRNA vaccines and especially BNT162b2, according to local protocols.

Inflammatory bowel diseases (IBD), which include Crohn’s disease (CD) and ulcerative colitis (UC), are characterized by chronic intestinal inflammation due to altered immunological response to commensal flora in genetically predisposed patients.5 Available treatment strategies include corticosteroids, immunomodulators (azathioprine, methotrexate), biologic agents (anti-TNF-α, anti-αβ7 integrin, anti-interleukin [IL]-12/23) and small molecules (JAK inhibitors).6 All such treatments induce variable degrees of immunosuppression, thus raising the possibility of inadequate responses to vaccines, including those against SARS-CoV-2. Indeed, suboptimal responses of patients with IBD with or without immunosuppression have been reported for influenza, pneumococcal, and hepatitis B vaccines; nevertheless, the particular type of therapy may also be of importance.

Patients with immune-mediated inflammatory diseases (IMIDs) who received systemic immunosuppressants were excluded from initial clinical trials of SARS-CoV-2 vaccines, and thus, data about efficacy and safety in this population are limited.3,13 There is, however, accumulating evidence that following SARS-CoV-2 vaccination, immunosuppressed patients such as on-treatment patients for IMIDs or oncological patients showed lower seroconversion rates than HCs.14,15 In addition, IBD patients treated with infliximab showed lower antibody levels after a single dose of the BNT162b2 and ChAdOx1 vaccines compared with patients treated with vedolizumab.16 In regards to safety, there were no specific signals after mRNA vaccination in IBD patients in comparison with non-IBD recipients, and adverse events (AEs) may even be less common among biologic-treated IBD patients.17,18

Taken together, the impact of IBD therapies on safety and efficacy of COVID-19 vaccines remains to be elucidated. We undertook the present study with the aim to investigate the immune response to vaccination against COVID-19 in a real-world setting involving Greek IBD patients.

**Materials and Methods**

**Patient and Control Groups**

Serum samples were collected from adult IBD patients that visited 8 tertiary IBD centers, either in outpatient or inpatient department and have completed COVID-19 vaccination with any of the available vaccine (BNT162b2 [Pfizer-BioNTEch], mRNA-1273 [Moderna/NIH], ChAdOx1 [AstraZeneca] and Ad26.Cov2.S [J&J]) at least 2 weeks before. Full vaccination regimen was defined as a 2-dose regimen for BNT162b2 (Pfizer-BioNTEch) 21 days apart, a 2-dose regimen for mRNA-1273 28 days apart, a 2-dose regimen for ChAdOx1 4 to 12 weeks apart and a 1-dose regimen for Ad26.Cov2.S. Inflammatory bowel disease diagnosis was confirmed by reviewing the medical files and was categorized as Crohn’s disease (CD), ulcerative colitis (UC), unclassified colitis (IBDU), and UC patients with ileal-pouch anal anastomosis (IPAA). Recruitment period was from May 1 to August 31, 2021. Accuracy of type and dates of vaccination were confirmed by authentic digital certificate provided to individuals by Greek authorities. Information regarding patients’ demographics, treatment, previous SARS-CoV-2 known infection, comorbidities and potential AEs after either vaccine dose (including pain at injection site, fatigue, allergy reaction, fever, lymphadenopathy, myalgia/arthritis, newly acquired diarrhea or abdominal pain, and headache) was also collected retrospectively. In our analysis, we included antibody levels from 124 healthy controls without previous history of COVID-19 who voluntarily took part in the study. Antibody levels in HCs were measured 1 month after the second dose of the vaccine (or the single dose in case of the J&J vaccine).

**Measurement of Anti-SARS-COV-2 Antibodies**

Antispike protein IgG S1 domain antibodies were measured with ELISA using a commercially available assay (Euroimmun Anti-SARS-CoV-2 QuantiVac ELISA [IgG]). Seroconversion was defined by manufacturer as a threshold of 11RU/mL.

**Ethical Considerations**

The study was conducted under the auspices of and funded from the Hellenic Group for the study of Idiopathic Inflammatory Bowel Diseases (EOMIFNE). The study protocol was approved by the institutional review boards of participating hospitals according to national legislation. All study participants provided informed consent.

**Statistical Analysis**

Continuous data are reported as median with interquartile range (IQR). For univariate analyses, Kruskal-Wallis test or Pearson correlation coefficient were used to identify demographic, vaccine, treatment, and adverse event factors associated with anti-S1 concentrations depending on the type of variables. Univariable logistic regression was used to identify factors associated with adverse events. Significant variables were entered in multivariable stepwise linear regression models to identify factors independently associated with anti-S1 levels and in a multivariable stepwise logistic regression model to identify factors independently associated with adverse events. A level of P < .05 was considered significant. Data were analysed using both MedCalc version 20.010 and IBM SPSS Statistics version 26.0.

**Results**

**Patient Characteristics**

Between May 1 and August 31, 2021, a total of 403 IBD patients (59% CD, 38% UC, 1% IBDU, and 2% with Ileal

---

Zacharopoulou et al
pouch-anal anastomosis) were recruited from 8 tertiary centers in regions across the country. Patient characteristics are shown in Table 1. Median age was 45 years (IQR, 34-56), median disease duration 8 years (4-15.25), and 53.4% of patients were male. More than half of patients (58.6%) were overweight (body mass index ≥25), the majority were nonsmokers (active smokers 25.8%), and one-third of patients reported comorbidities. Seven patients (2.6%) reported history of COVID-19 infection, which was confirmed by appropriate testing.

Overall, IBD treatments included single biologic therapy (296 patients, 73.4%), single immunomodulators (azathioprine/MP/Methotrexate, 28 patients, 6.9%), and combination of biologic plus immunomodulator (49 patients, 12.2%); 70 patients did not receive any immunosuppressive agent (17.4%).

**Patients With IBD Show High Seroconversion Rates But Diminished Antibody Responses After Anti-SARs-CoV-2 Vaccination**

Antibody testing was conducted at a median of 31 days (IQR 23-46) after completion of the vaccination protocol with any of the available vaccines. Most patients received BNT162b2 (340 patients, 84.4%), whereas the rest were vaccinated with ChAdOx1 (41 patients, 10.2%), Ad26.Cov2.S (15 patients, 3.7%), and mRNA-1273 (6 patients, 1.5%).

In total, we observed that 98.0% of patients seroconverted following full vaccination with any of the available vaccines. Seroconversion rate in our HCAs cohort was 93.5% (P = .011). Nevertheless, we observed that IBD patients had significantly lower antibody concentrations than HCAs (RU/mL 108 vs 132.7 RU/mL, P = .0001). Interestingly, further analysis revealed that the group of IBD patients without immunosuppression also had lower anti-S1 IgG levels than HCAs (117.1 RU/mL vs 132.7 RU/mL; P = .046; Figure 1a).

**Seroconversion Rates and Magnitude of Antibody Response According to Type of Vaccine**

Patients who received mRNA vaccines showed higher seroconversion rates than those who received viral vector vaccines (98.6% vs 93.6%, P = .021). The BNT162b2 vaccination demonstrated the highest seroconversion rate (98.8%), followed by ChAdOx1 (97.6%), mRNA-1273 (93.3%), and Ad26.Cov2.S (66.7%).

Overall, the median anti-SARS-CoV-2 IgG S1 antibody concentration in IBD patients was 108 RU/mL. Median antibody concentrations were higher following mRNA vaccines (BNT162b2 or mRNA-1273) than viral vector vaccines (ChAdOx1 or Ad26.Cov2.S; 111.2 RU/mL vs 76 RU/mL, P < .001; Figure 1b). No statistical differences were observed in antibody concentrations between the 2 mRNA vaccines (medians: BNT162b2, 111.2 RU/mL; mRNA-1273, 117.4 RU/mL) or between the 2 viral vector vaccines (medians: ChAdOx1, 80.4 RU/mL; Ad26.Cov2.S, 18 RU/mL, respectively; Figure 2).

**Factors Associated With Antibody Response in IBD Patients**

We initially compared postvaccination serum anti-S1 antibodies between IBD patients who did or did not receive immunosuppressive therapy, including biologics, immunomodulators (IMMs) or systemic corticosteroids. We found that patients without immunosuppression had higher antibody titers (median, 117.1 RU/mL vs 106.2 RU/mL in patients on immunosuppression; P = .012; Figure 1a).

In the univariate analysis (Table 2), Crohn’s disease, viral vector vaccines, older age, and longer time between vaccination and antibody measurement were associated with lower anti-S1 titers. As far as type of IBD treatment is concerned, we observed significantly lower antibodies in patients treated with systemic corticosteroids (P = .017), IMMs (P = .015), anti-TNFα (P = .016), combination of biologic plus IMMs (P = .009), or any 2 immunosuppressive agents (P = .006). In contrast, vedolizumab (VDZ)-treated patients demonstrated higher antibody concentrations compared with all other treatments (median 119.2 vs 106, P = .027). Interestingly, patients receiving methotrexate (MTX) but not thiopurines showed lower antibody levels compared with all other treatments (P = .020). In regards to type of IBD, patients with UC showed higher antibody levels than patients with CD (113.8 RU/mL vs 103.8 RU/mL, P = .030).

In our multivariate model, we confirmed that mRNA vaccines are associated with higher antibody levels (P < .001). In addition, older age (P = .016), longer timing of antibody measurement after vaccination (P < .001) and treatment with anti-TNF (P = .013) were negatively associated with anti-S1 concentrations (Table 3).

**Comparative Analysis of the Effect of Different Biologics on Antibody Response to Vaccination**

To specifically dissect the effect of biological therapy on vaccination response, we compared antibody concentrations between patients who were on monotherapy with any of the currently available biologics at the time of vaccination. Our analysis showed that IBD patients treated with VDZ had higher serum concentrations of anti-SARS-CoV-2 IgG antibodies (median concentration, 121 RU/mL) than those treated with anti-TNFα (106.8 RU/mL, P = .023) or ustekinumab (UST) monotherapy (95.9 RU/mL, P = .032; Supplementary Figure 1). No difference was seen between anti-TNFα- and UST-treated patients or between intravenous (infliximab) and subcutaneous (adalimumab) anti-TNFα therapies.

There was no observed correlation between antibody titers and distance from previous or next biologic treatment in days.

In our cohort, there were 7 patients with IBD and confirmed previous COVID-19 disease who all received BNT162b2 mRNA vaccine. There was no statistically significant difference regarding the levels of anti-SARS-CoV-2 IgG S1 antibodies postvaccination between those patients and patients without a history of infection (median, 124.7 RU/mL vs 109.1 RU/mL, respectively, P = .232).

Further analysis on anti-S1 levels in IBD patients was conducted regarding the timing of serum collection following vaccination (Supplementary Figure 2). We observed that anti-S1 levels were significantly lower when measured more than 56 days after vaccination, when all vaccine types were analyzed (P = .011). When only mRNA-vaccinated patients were analyzed, we detected that the antibody response wanes significantly after 53 days postvaccination (P = .049; Supplementary Figure 3). Such analysis did not achieve significant results in viral vector-vaccinated patients, possibly due to the smaller number of this cohort.
Table 1. Demographic and Clinical Characteristics of Participants.

| Characteristic                              | IBD Patients N = 403 | Healthy Controls N = 124 | P     |
|---------------------------------------------|----------------------|--------------------------|-------|
| Age (years; median [IQR])                  | 45 (34-56)           | 51 (48-54)               | 0.001 |
| Gender                                      |                      |                          |       |
| Male                                        | 215 (53.4%)          | 52 (42%)                 | 0.026 |
| Female                                      | 188 (46.7%)          | 72 (58%)                 |       |
| Diagnosis                                   |                      |                          |       |
| Crohn’s disease                             | 237 (58.8%)          |                          |       |
| Ulcerative colitis                          | 153 (38%)            |                          |       |
| IBD unclassified                            | 4 (1%)               |                          |       |
| Ileal pouch                                 | 7 (1.7%)             |                          |       |
| Disease duration (years; median [IQR])      | 8 (4-15.25)          |                          |       |
| Age at IBD diagnosis (years; median [IQR])  | 34 (24-46)           |                          |       |
| BMI [kg/m²; median (IQR)]                   | 25.8 (22.8-29.3)     |                          |       |
| Current Smokers (N, %)                      | 104/363 (25.8%)      |                          |       |
| Comorbidities (N, %)                        | 153 (38%)            | 67 (16.6%)               |       |
| Cardiovascular disease                      | 38 (9.4%)            |                          |       |
| Diabetes mellitus                           | 27 (6.7%)            |                          |       |
| Rheumatic disease                           | 43 (10.7%)           |                          |       |
| Kidney failure                              | 0                    |                          |       |
| Liver disease                               | 6 (1.5%)             |                          |       |
| Respiratory disease                         | 18 (4.5%)            |                          |       |
| Cancer-hematologic disease                  | 6 (1.5%)             |                          |       |
| Hypertension                                | 30 (7.4%)            |                          |       |
| Hyperlipidemia                              | 25 (6.2%)            |                          |       |
| Other                                       | 67 (16.6%)           |                          |       |
| Treatment (N, %)                            | 135 (33.5%)          |                          |       |
| 5-ASA                                       |                      |                          |       |
| Systemic corticosteroids                    | 15 (3.7%)            |                          |       |
| Thiopurines                                 | 53 (13.2%)           |                          |       |
| Methotrexate                                | 24 (6%)              |                          |       |
| Infliximab                                  | 134 (33.3%)          |                          |       |
| Adalimumab                                  | 51 (12.7%)           |                          |       |
| Golimumab                                   | 3 (0.7%)             |                          |       |
| Vedolizumab                                 | 71 (17.6%)           |                          |       |
| Ustekinumab                                 | 33 (8.2%)            |                          |       |
| Tofacitinib                                 | 3 (0.7%)             |                          |       |
| IMM monotherapy                             | 28 (6.9%)            |                          |       |
| Anti-TNFα monotherapy                       | 153 (38%)            |                          |       |
| Anti-TNFα + IMM                             | 39 (9.7%)            |                          |       |
| Biologic monotherapy                        | 247 (61.3%)          |                          |       |
| Biologic + IMM                              | 49 (12.2%)           |                          |       |
| Two immunosuppressive agents                | 55 (13.6%)           |                          |       |
| Three immunosuppressive agents              | 2 (0.5%)             |                          |       |
| No immunosuppression                        | 70 (17.4%)           |                          |       |
| Vaccine name (N, %)                         | BNT162b2 (Pfizer)     | 340 (84.4%)              |       |
| mRNA-1273 (Moderna)                         | 15 (3.7%)            |                          |       |
| ChAdOx1 (AstraZeneca)                       | 41 (10.2%)           |                          |       |
| Ad26.CoV2.S (Johnson&Johnson)               | 6 (1.5%)             |                          |       |
| Vaccine type (N, %)                         | mRNA (BNT162b2 & mRNA-1273) | 355 (88.1%)              |       |
| Viral vector (Ad26.CoV2.S & ChAdOx1)        | 47 (11.7%)           |                          |       |
| Prior positive test for COVID-19 (N, %)     | 7 (1.73%)            |                          |       |
| Days from last vaccine (median [IQR])       | 31 (23-46.75)        |                          |       |

Abbreviations: BMI, body mass index; COVID-19, corona virus disease 2019; IQR, interquartile range; IMM, immunomodulator (methotrexate, thiopurines); N, number.
Factors Affecting Antibody Responses to Different Types of Vaccination
We also conducted a separate subanalysis on antibody responses in patients who received either mRNA or viral vector vaccines, exclusively (Supplementary Table 2). In the mRNA-vaccinated cohort, treatment with anti-TNFα ($P = .008$) and combination treatment with biologics plus IMMs ($P = .021$) was independently associated with lower antibody titers when all significant factors were analyzed. In addition, we confirmed that older age was also correlated with attenuated vaccine response ($P = .014$). With respect to viral vector vaccines, none of the factors was significantly correlated to lower anti-S1 levels in the univariate analysis. We hypothesize that the small number of patients who received viral vector vaccines may preclude identification of additional associations.

Safety and Adverse Events
We collected data on immediate and short-term adverse events using a questionnaire at the time of serum collection (available data on 362 patients). No serious AEs observed during the observation period and only minor AEs were reported, as shown in Supplementary Table 4. After the first vaccine dose, 79.4% of respondents reported an AE (47.3% excluding pain at the injection site). The most common reported AEs after the first dose were pain at the site of injection (73%), fatigue (38%), and myalgia/arthralgia (19%). Following the second vaccine dose (available data on 350 patients), 72% of patients reported an AE (49% excluding pain at the injection site). The most common reported AEs after the second dose were pain at the site of injection (63.1%), fatigue (40%), myalgia/arthralgia (23.7%), fever (18%), and headache (16%). We analyzed the correlation between presence of AEs after the second vaccine dose and patient characteristics (Supplementary Table 3). In the multivariate analysis younger age, female gender and mRNA vaccines were significantly correlated to AEs following the second vaccine dose ($P = .003$, $P < .001$, and $P = .001$, respectively), although a tendency was observed for BMI without reaching statistical significance threshold ($P = .052$; Table 4).

Discussion
Herein, we report high seroconversion rates in Greek patients with IBD following complete vaccination with any of the available anti-SARS-CoV-2 vaccines (2 doses of BNT162b2, mRNA-1273 or ChAdOx1 or 1 dose of Ad26.CoV2.S, respectively). In fact, our analysis showed that seroconversion rates for individual vaccines were similar or even higher to those reported in the general population. Recently, Hadi et al reported that mRNA vaccination is as efficacious in IBD patients, even in biologic-treated ones, as in general population. In our cohort, the highest seroconversion rates were obtained with 2 doses of BNT162b2 mRNA vaccine compared with other vaccine types. This result is in line with a recent study from the Israeli IBD group that reported 100% seropositivity in 185 IBD patients 2 weeks after the second dose of BNT162b2 mRNA vaccine. On the other hand, the single-dose Ad26.CoV2.S vaccination regimen demonstrated the lowest seroconversion rate, which has been reported in previous literature. However, the fact that our cohort included only 6 patients receiving Ad26.CoV2.S vaccine may influence our result. Finally, we observed that in our IBD cohort, 2 doses of ChAdOx1 vaccination resulted in higher seroconversion rates than previously reported in HCs (70.4% efficacy). Indeed, there is accumulating evidence that IBD patients on biologic treatments demonstrate high seroconversion rates after ChAdOx1 vaccination.
| Variable                                                                 | IBD patients       | HC                      |
|------------------------------------------------------------------------|--------------------|-------------------------|
|                                                                        | n/N    | Correlation Coefficient rho | P     | Correlation Coefficient rho | P     |
| Age                                                                    | 403/403 | -0.136                   | 0.007 | -0.073                     | 0.497 |
| BMI                                                                    | 374/403 | 0.045                    | 0.385 |
| Timing of serum analysis from last vaccine dose                        | 403/403 | -0.208                   | <0.001|
| Timing of 1st vaccine dose from last biologic administration           | 168/403 | -0.006                   | 0.940 |
| Timing of 1st vaccine dose from next biologic administration           | 183/403 | -0.056                   | 0.452 |
| Timing of 2nd vaccine dose from last biologic administration           | 171/403 | -0.047                   | 0.539 |
| Timing of 2nd vaccine dose from next biologic administration           | 172/403 | 0.021                    | 0.787 |
| Gender                                                                 | n/N    | Median RU/mL (IQR)       | P     | Median RU/mL (IQR)         | P     |
| male                                                                   | 215/403 | 107 (82 -128.4)          | 0.134 | 139.2 (88.4-909.5)         | 0.091 |
| female                                                                 | 188/403 | 109.7 (88.2-132.9)       |       | 122.0 (43.0-406.8)        |       |
| Disease                                                                | n/N    | Median RU/mL (IQR)       | P     | Median RU/mL (IQR)         | P     |
| CD                                                                     | 237/403 | 103.8 (76.9-130.6)       | 0.030 | (UC vs CD)                 |       |
| UC                                                                     | 153/403 | 113.8 (92.2-133)         |       | 0.064                     |       |
| IBDU                                                                   | 4/403  | 102.8 (93.7-118.8)       |       | 0.530                     |       |
| IPAA                                                                   | 7/403  | 109.8(91.7-133.8)        |       | 0.057                     |       |
| Smoking                                                                | n/N    | Median RU/mL (IQR)       | P     | Median RU/mL (IQR)         | P     |
| Smoking                                                                | 104/363| 107.8 (80.5-128.3)       | 0.114 |
| Treatment                                                              | n/N    | Median RU/mL (IQR)       | P     | Median RU/mL (IQR)         | P     |
| S-ASA                                                                  | 135/403| 115.4 (93.7-130)         | 0.040 |
| Budesonide                                                             | 15/403 | 113.8 (95.3-133.8)       | 0.357 |
| Systemic CS                                                            | 15/403 | 90.9 (52.5-105.8)        | 0.017 |
| Thiopurines                                                            | 53/403 | 106.2 (86.9-122.8)       | 0.283 |
| Methotrexate                                                           | 24/403 | 84.9 (60.2-117.4)        | 0.020 |
| IMM's monotherapy                                                      | 28/403 | 104.2 (88.7-126.2)       | 0.720 |
| IMM's                                                                  | 78/403 | 97.3 (77-121.7)          | 0.015 |
| Biologic therapy                                                       | 296/403| 107 (79.5-130.3)         | 0.139 |
| Biologics monotherapy                                                  | 247/403| 107.7 (84.4-132.7)       | 0.530 |
| Biologic in combination with IMM's                                     | 49/403 | 91 (60.8-121.5)          | 0.009 |
| Infliximab                                                             | 134/403| 102.6 (68-125.9)         | 0.007 |
| Adalimumab                                                             | 51/403 | 103.8 (64-131.8)         | 0.485 |
| Golimumab                                                              | 3/403  | 143.1 (121.9-143.9)      | 0.104 |
| Anti-TNFr                                                             | 191/403| 104.2 (68.5-128.7)       | 0.016 |
| Anti-TNFr monotherapy                                                  | 153/403| 106.8 (74.3-132)         | 0.393 |
| Anti-TNFr + IMM's                                                     | 39/403 | 90 (58.5-123)            | 0.014 |
| Vedolizumab                                                            | 71/403 | 119.2 (95.9-138.4)       | 0.027 |
| Vedolizumab monotherapy                                               | 66/403 | 98.5 (121-139.9)         | 0.009 |
| Vedolizumab + IMM's                                                   | 3/403  | 31.7 (103.1-115.6)       | 0.264 |
| Ustekinumab                                                           | 33/403 | 99.2 (86.4-117.4)        | 0.371 |
| Ustekinumab monotherapy                                              | 28/403 | 95.9 (85.8-119.8)        | 0.329 |
| Ustekinumab + IMM's                                                  | 5/403  | 111.9 (100.8-115.3)      | 0.980 |
| JAK inhibitors                                                        | 3/0403 | 90.9 (71.4-105.8)        | 0.337 |
| Two immunosuppressive agents                                          | 55/403 | 91 (62.2-121.6)          | 0.006 |
| Three immunosuppressive agents                                        | 2/403  | 59.7 (45.4-73.9)         | 0.085 |
| No immunosupression                                                   | 70/403 | 117.1 (98.4-136.8)       | 0.012 |
| Common morbidities                                                    | n/N    | Median RU/mL (IQR)       | P     | Median RU/mL (IQR)         | P     |
| Any                                                                    | 154/403| 105.9 (79.9-127)         | 0.214 |
| Cardiovascular                                                        | 38/403 | 94.2 (69.9-108)          | 0.004 |
| Diabetes mellitus                                                     | 27/403 | 98.2 (64.7-109.4)        | 0.061 |
| Reumatological                                                        | 43/403 | 94.3 (63.9-130.6)        | 0.252 |
| Liver disease                                                         | 6/403  | 119.2 (113.3-133.4)      | 0.369 |
| Hyperlipidemia                                                        | 25/403 | 94 (71.3-118.3)          | 0.043 |
| Hypertension                                                          | 30/403 | 109 (93.6-127)           | 0.615 |
| Respiratory disease                                                   | 18/403 | 104 (90.6-138.2)         | 0.780 |
| Cancer-hematological disease                                          | 18/403 | 120.6 (101.2-133.4)      | 0.538 |
Table 2. Continued

| Variable                        | IBD patients | HC                      |                   |
|---------------------------------|--------------|-------------------------|-------------------|
|                                 | n/N          | Correlation Coefficient | 95% CI for Beta   |
|                                 |              | rho                     |                   |
| AEs after 1st vaccine dose      |              |                         |                   |
| Any                             | 286/362      | 92.9 (112.3-133.4)      | 0.024             |
| Arm pain                        | 256/356      | 114 (94-135.2)          | 0.003             |
| Allergy                         | 114 (94-135.2)|                         |                   |
| Fatigue                         | 154/356      | 117.3 (92.2-136.8)      | 0.075             |
| Fever                           | 63/356       | 106.2 (126.4-144.8)     | <0.001            |
| Lymph nodes                     | 16/356       | 105.5 (125.1-146.3)     | 0.095             |
| Headache                        | 86/356       | 106.7 (126.3-135.6)     | 0.005             |
| Myalgia arthralgia              | 83/356       | 121.7 (103.1-133.4)     | 0.01              |
| Abdominal pain                  | 19/356       | 87.7 (96.3-139)         | 0.348             |
| Diarrhea                        | 25/356       | 90.4 (87.4-128.8)       | 0.124             |
| COVID-19                        | 7/403        | 124.7 (96.6-142.7)      | 0.232             |
| Vaccine type                    | mRNA         | 356/403                 | 111.6 (90.2-133.1)| <0.001 |
| Viral vector                    | 47/403       | 76 (36.3-97.8)          |                   |

Table 3. Multivariate Linear Regression of Factors Associated With Anti-S1 IgG Antibodies (RU/mL).

| Variable                        | Standardized Coefficients Beta | 95% CI for Beta |
|---------------------------------|-------------------------------|-----------------|
| Age (in years)                  | -0.5                          | -1.0            |
| Days elapsed since vaccination  | -0.7                          | -1.0            |
| mRNA vs Vector                  | 46.2                          | 25.7            |
| anti-TNF                         | -16.5                         | -29.6            |

The variables disease type, adverse events after the second dose, two immunosuppressive agents, biologic in combination with IMMs, anti-TNF + immunomodulator, infliximab, vedolizumab, vedolizumab monotherapy, methotrexate, systemic corticosteroids, immunomodulators, no immunosuppression, cardiovascular disease, hyperlipidaemia were also added to the multivariate model, but they were excluded during the stepwise procedure. Abbreviations: Anti-TNFα, anti-tumor necrosis α; CI, confidence interval; IMM, immunomodulator.

Serocoversion rate of our HCs cohort was similar to previously reported according their median age. In comparison, our IBD patients had higher seroconversion rates in total, which may be explained by their younger age.

Despite high seroconversion rates, the magnitude of response to anti-SARS-CoV-2 vaccination was lower in IBD patients than in HCs, irrespective of the type of treatment. Interestingly, we also confirmed that IBD patients without immunosuppression had lower anti-S1 IgG levels than HCs, suggesting that IBD per se leads to impaired immune responses. There are scarce data on inherent alterations regarding vaccine responses in IBD patients irrespective of immunosuppressive treatment. Further research is needed to elucidate the magnitude, characteristics, and mechanisms of such immunogenicity impairment in patients with IBD.

A major finding that we report herein is that patients who were on treatment with anti-TNFα monoclonal antibodies, either as monotherapy or in combination with IMMs, had significantly lower antibody levels compared with all other treatments. Our results also align with the recent report from the REsponses to COViD-19 vaccinE IsRaeli IBD group (RECOVERI) who assessed 185 IBD patients and found that anti-S levels were significantly lower in patients treated with anti-TNFα compared with patients not treated with anti-TNFα or HCs. We conducted further comparison between IFX- and ADA-treated IBD patients, and we report, for the first time, that there was no significant difference in anti-S1 IgG levels between the 2 groups. This finding extends previous evidence that patients treated with IFX or ADA show similar levels of antinucleocapsid antibodies after SARS-CoV-2 infection. Taken together, those data indicate that intravenous and subcutaneous anti-TNFα therapy affect the immune response in a similar way.

An important and novel parameter of our current work is the comparative analysis of the effect of individual biologics on antibody responses after anti-SARS-CoV-2 vaccination. Our analysis showed that patients on VDZ had significantly higher anti-S1 IgG antibody titers in comparison with patients treated with either anti-TNFα or UST, whereas no difference was seen between the 2 latter groups. Such differences most probably reflect the diverse immunological effects of specific biologics, being gut-selective for VDZ and systemic in the case of anti-TNFα or anti-IL12/23 blockade. In that sense,
our findings align with previous work by Kennedy et al who compared antispike antibodies between IBD patients treated with either IFX or VDZ 2 to 10 weeks after vaccination with a single dose of mRNA vaccines; they found that IFX treatment was associated with lower antibody titers than VDZ.

With regards to IMMs, it has been reported that their use was independently associated with lower immunogenicity rates to mRNA vaccines.\(^{16}\) However in our analysis, we did not reach any such conclusion.

Wong et al analyzed sera from 48 IBD patients, mostly on biologic therapy, who received 1 or 2 doses of mRNA vaccines; their study showed that following a 2-dose regimen, there was no association between anti-IgG levels and timing of biologic therapy.\(^{28}\) We verified these results, as we found no significant correlation between anti-S IgG titers and distance from previous or next biologic treatment.

We also confirmed older age as a factor that is associated with attenuated vaccine response in IBD patients, as previously reported in published literature.\(^{16}\)

Our study reported excellent safety profiles of all COVID-19 vaccines in patients with IBD, irrespective of treatment. In our cohort, we observed AE rates similar to those previously reported\(^{20}\) and recorded no serious AEs. We did not see any myocarditis cases among 11 males younger than 21 years old and no thromboembolic events among 41 females older than 60 years old. Moreover, there was no significant increase of symptoms suggestive of IB exacerbation, like diarrhea or abdominal pain in the period after vaccination. In the multivariate analysis of mRNA vaccines, younger age and female gender were significantly correlated to AEs following the second vaccine dose. These factors are known to positively correlate with post-COVID vaccination AEs.\(^{29}\) On the contrary, biologic therapy has been associated with less common AEs.\(^{18}\) Conflicting data exist in the literature regarding the effect of treatment with biologics, with some studies reporting fewer AEs in IBD patients treated with anti-TNFα, and other showing no correlation.\(^{17,20,30,31}\) We did not find similar associations in our study. The role of immunosuppressive treatment in AE rate following anti-SARS-Cov-2 vaccination is yet to be elucidated.

Irrespective of treatment, we demonstrated that antibody levels wane as time goes by. This goes in line with a recent observation that immune humoral response to BNT162b2 COVID-19 vaccine declines after 6 months, more importantly in male, elderly, and immunocompromised patients.\(^{32}\) This observation is significant in order to produce vaccination protocols, especially for immunosuppressed patients. In addition, we did not manage to correlate prior COVID-19 infection with the presence of AEs possibly because of the low rate of prior infection in our cohort (7 patients).

There are several strengths in our study. First, this is the largest adult IBD cohort assessed prospectively for both antibody production and AEs after full vaccination protocol with all 4 EMA approved vaccines (BNT162b2 [Pfizer-BioNTech], mRNA-1273 [Moderna/NIH], ChAdOx1 [Astra Zeneca] and Ad26.Cov2.S [J&J]). It is also the only cohort that collected data about comorbidities along with other demographic details. In addition, statistical analysis included patients with all types of medications and even an important cohort of IBD patients without immunosuppression. Thus, we managed to extract results for all available drugs, including systemic corticosteroids and newer biologics. We focused on not only intravenous therapies but also subcutaneous treatments, allowing for further statistical analysis. Furthermore, we included a large number of HCs, allowing for further comparisons. Another strength is that we obtained data on the timing of vaccination along with the timing of biologic infusion or injection, providing evidence that there is no significant correlation between these time points and anti-S1 IgG production.

However, our study is also limited by certain factors. First, the fact that recruited patients were from tertiary IBD centers suggests that disproportionately more patients on treatment with biologics and/or high disease burden were included. Second, we did not check for prior COVID-19 infection by testing collected sera for antinucleocapsid antibodies but relied on appropriate nasopharyngeal or nasal test reporting. However due to government protocols, most of the patients conducted these tests very often in order to work or enter the hospital. Third, we did not obtain data on vaccine type for HCs, and there is a difference in gender ratio and age distribution between IBD and HC groups. However, this difference may not hamper our results, as we did not correlate the antibody concentrations with male or female gender, and HCs demonstrated higher antibody levels irrespective of the fact that they had older median age. Fourth, we obtained small sample size for some specific subgroup analysis. Finally, as far as vaccine efficacy is concerned, we assessed only anti-S1 antibodies, and we did not address neutralization of SARS-CoV-2 with other methods. Nonetheless, the ELISA we used shows very good agreement compared with available neutralization tests, according to manufacturer details.

### Conclusion

Our study provides prospective controlled data on the antibody production after COVID-19 vaccination with all 4 EMA approved vaccines, suggesting that mRNA vaccines are more efficacious in IBD patients than viral vector ones and that all vaccines are safe in this population. We demonstrated that patients treated with anti-TNFα and UST have lower antibody levels than patients treated with VDZ. More importantly, the fact that IBD patients without immunosuppression have lower antibody concentrations than HCs confirms the observation that patients with IMIDs have altered immune response. However, the actual deficit in vaccine efficacy is not known, and further long-term research is needed to address this question. Until then, attention should be paid to promote vaccination in IBD patients, even those that do not currently receive immunosuppressive drugs. Vaccination protocols should be updated taking into account the waning of antibody levels as time goes by.

### Funding

The study was conducted under the auspices of and funded from the Hellenic Group for the study of Idiopathic Inflammatory Bowel Diseases (EOMIFNE) (2021EOMIFNEmp1).

### Conflicts of Interest

E.Z.: Lecturer for Amgen, Takeda
Antibody Production After anti-SARS-CoV-2 vaccination

M.T.: Advisor/lecturer for Janssen, Pfizer, Takeda, Abbvie, MSD, Mylan, Genesis Pharma, Amgen, Research/Clinical Trials: Abbvie, Gilead, Takeda

N.V.: Advisor/lecturer for Janssen, Pfizer, Aenorasis, Takeda, Abbvie, MSD, Mylan, Amgen, Genesis Pharma, Cooper.

G.J.M.: Advisor/lecturer for Abbvie, Celgene, Celtrion, Ferring, Genesis, Hospira, Janssen, Millennium Pharmaceuticals, MSD, Mylan, Pharmacosmos, Pfizer, Takeda, VIANEX, Angelini, Falk Pharma, Galenica, Omega Pharma; Consultancies for MSD and Takeda; Research support from Abbvie, Galenica, Genesis, Menarini Group, MSD, Pharmathen.

K.K.: Advisor/lecturer for Abbvie, Aenorasis, Janssen, MSD, Pfizer and Takeda, Amgen, Ferring, Galenica, Genesis Pharma.

E.Z.: Advisor/lecturer for Pfizer, Takeda, Abbvie, Amgen, Genesis Pharma, Aenorasis, Janssen

S.M.: Advisory/Lecturer for Pfizer, Takeda, Abbvie, Ferring, MSD, Janssen

G.M.: Lecturer for Janssen, Takeda, MSD, Abbvie, Pfizer P.K.: Lecturer for Takeda, Janssen, Amgen, Ferring C.L.: Advisor/lecturer for MSD, BOSTON SCI, Research/ Clinical Trials: Epsilon Health Co

I.E.K.: Advisor for Abbvie, Astelas, Genesis, Janssen, MSD, Pharmacosmos, Pfizer, Shire, Vianex and Takeda; Lecturer for Abbvie, Astelas, Genesis, Janssen, MSD, Vianex Takeda and Viatris; research support Abbvie, Vianex, Unipharma, Viatris, Takeda and Ferring

G.B.: Advisor/lecturer for Janssen, Pfizer, Takeda, Abbvie, MSD, Mylan, Genesis Pharma, Adacysite Therapeutics, Amgen, Ferring, Cooper; Funding (Grants/Honoraria): Pfizer, Takeda, Abbvie, Aenorasis; Research/Clinical Trials: Abbvie, Takeda.

E.O., G.T., V.K., E.A., A.C., M.T., A.T., E.P., S.T., E.L., I.M., N.K., T.K., G.T: nothing to disclose

References

1. Coronavirus Vaccine Tracker. Accessed February 5, 2022. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–416.

3. Polack PF, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–2615.

4. Sadoff J, Gray G, Vandenbosh A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384:2187–2201.

5. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.

6. Limbergen J Van, Radford-Smith G, Satsangi J. Advances in IBD genetics. Nat Rev Gastroenterol. Hepatol. 2014;11:372–385.

7. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J. Crohns. Colitis 2020;14:4–22.

8. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:148–154.

9. Debrun JCC, Hilsen R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflammm Bowel Dis. 2012;18:25–33.

10. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study. Inflamm Bowel Dis. 2012;18:1042–1047.

11. Andrisani G, Frasca D, Romero M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti-TNFα agents: Effects of combined therapy with immunosuppressants. J Crohn’s Colitis. 2013;7:301–307.

12. Kucharzik T, Ellul P, Greuter T, et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J. Crohn’s Colitis. 2021;15:879–913.

13. Folegatti PM, Ewer KL, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478.

14. Jena A, Mishra S, Deepak P, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmun Rev. 2022;21:102927.

15. Monin I, Laing AG, Muñoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765–778.

16. Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut 2021;70:1884–1893.

17. Hadi YB, Thakkar S, Shah-Khan SM, et al. COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States. Gastroenterology 2021;161:1336–1339.

18. Botwin GJ, Li D, Figueiredo J, et al. Adverse events after SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol. 2021;116:1746–1751.

19. European Medicines Agency. Accessed February 5, 2022. https://www.ema.europa.eu.

20. Edelman-Klapper H, Zittran E, Bar-Gil Shitrit A, et al. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with Anti-TNFα. Gastroenterology 2021;162:454–467.

21. McDonald I, Murray SM, Reynolds CJ, et al. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. npj Vaccines. 2021;6:74.

22. Pozdnjakova V, Botwin GJ, Sobhani K, et al. Decreased antibody responses to Ad26.COV2.S relative to SARS-CoV-2 mRNA vaccines in patients with inflammatory bowel disease. Gastroenterology 2021;161:2041–2043.

23. Boyarsky BJ, Chiang TPY, Ou MT, et al. Antibody response to the Janssen COVID-19 vaccine in solid organ transplant recipients. Transplantation. 2021;105:82–83.

24. Shehab M, Alrashed F, Alfadhli A, et al. Serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with inflammatory bowel disease on biologic therapies; a multi-center prospective study. medRxiv 2021.

doi:10.1101/2021.10.31.21265718

25. Wei J, Stoeresser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021;6:1140–1149.

26. Cossio-Gil Y, Martinez-Gómez X, Campins-Martí M, et al. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination. J Gastroenterol Hepatol. 2015;30:92–98.

27. Chanchlani N, Lin S, Chee D, et al. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 biologic-treated patients. J. Crohn’s Colitis. 2021;16:389–397.

28. Wong S-Y, Dixon R, Martinez Pazos V, et al. Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies. Gastroenterology 2021;161:715–718.e4.
29. Gee J, Marquez P, Su J, et al. First month of COVID-19 vaccine safety monitoring — United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:283–288.
30. Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence. J Am Acad Dermatol. 2021;85:1274–1284.
31. Orfanoudaki E, Zacharopoulou E, Kitsou V, et al. Real-world use and adverse events of SARS-CoV-2 vaccination in Greek patients with inflammatory bowel disease. J. Clin. Med 2022;11:641.
32. Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385:e84.